Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis (ERADIAS)
|ClinicalTrials.gov Identifier: NCT01062737|
Recruitment Status : Completed
First Posted : February 4, 2010
Last Update Posted : February 4, 2010
|Condition or disease||Intervention/treatment||Phase|
|Hip Osteoarthritis||Drug: ASU||Phase 3|
Primary hip OA, fulfilling ACR criteria, patient over 45 y, painful > 1 year, Lequesne's index > or equal to 3, with minimum JSW at the target hip > 1 mm and < 4 mm on pelvic radiograph.
Primary criterion of efficacy:
The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader.
Randomisation is stratified according JSW at baseline (< 2,5 mm or > or equal to 2,5 mm).
The Full Analysis Set (FAS) is defined by patients with at least one baseline value and one post baseline value.
The main analysis is scheduled on FAS using a Missing At Random (MAR)with a multiple model repeated measure (MMRM)to take in account missing value.
SAP (Statistical Analysis Plan) schedule to analyse JSW change as quantitative variable using an ANCOVA and as qualitative variable (progressors defined as JSW loss upper than 0,5 mm) using Mantel Haentzel test.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial|
|Study Start Date :||December 1999|
|Primary Completion Date :||September 2006|
|Study Completion Date :||September 2006|
|Experimental: ASU (Avocado Soybean Unsaponifiable)||Drug: ASU|
- The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062737